FibroGen Inc (FGEN) Given Average Rating of “Buy” by Analysts

FibroGen Inc (NASDAQ:FGEN) has earned an average recommendation of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $65.67.

A number of equities research analysts have issued reports on FGEN shares. Mizuho reiterated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a research note on Friday. Finally, BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st.

Shares of FibroGen (NASDAQ:FGEN) opened at $53.20 on Tuesday. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $4,582.51, a price-to-earnings ratio of -26.08 and a beta of 1.74. FibroGen has a 12 month low of $22.70 and a 12 month high of $63.00.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.13). FibroGen had a negative return on equity of 47.36% and a negative net margin of 120.00%. research analysts anticipate that FibroGen will post -1.75 earnings per share for the current fiscal year.

In other news, Director Gerald Lema acquired 3,500 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was purchased at an average price of $46.70 per share, for a total transaction of $163,450.00. Following the completion of the transaction, the director now directly owns 3,500 shares in the company, valued at approximately $163,450. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 18,900 shares of the firm’s stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $48.29, for a total value of $912,681.00. Following the transaction, the chief executive officer now owns 3,071,705 shares of the company’s stock, valued at approximately $148,332,634.45. The disclosure for this sale can be found here. Insiders sold a total of 328,917 shares of company stock valued at $16,142,651 in the last quarter. 13.60% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of FGEN. Bank of Montreal Can grew its position in shares of FibroGen by 2,097.2% during the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. grew its position in shares of FibroGen by 95.0% during the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of FibroGen by 41.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 1,147 shares in the last quarter. Finally, Amalgamated Bank purchased a new position in shares of FibroGen during the second quarter valued at about $237,000. Hedge funds and other institutional investors own 57.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FibroGen Inc (FGEN) Given Average Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/06/fibrogen-inc-fgen-given-average-rating-of-buy-by-analysts-2.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply